ArticleMedical oncology (Northwood, London, England)2025
Deciphering the crucial role of IGF2BP3 in modulating stemness traits of salivary adenoid cystic carcinoma.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Salivary adenoid cystic carcinoma (SACC) is a rare yet clinically vexing malignancy characterized by perineural invasion, late lung-dominant metastasis, and limited systemic options, underscoring the need for mechanistic targets specific to SACC. This study employs a systematic experimental approach to elucidate the functional role and regulatory mechanisms of insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) in SACC cells. Initial validation confirmed elevated IGF2BP3 expression in SACC tumor tissue, with knockdown of IGF2BP3 markedly suppressing cell proliferation, clonogenicity, and migratory capacity in SACC cells. Subsequent RNA sequencing analysis revealed the downregulation of stemness pathways upon IGF2BP3 knockdown, corroborating its regulatory role in SACC stemness. Leveraging single-cell sequencing data, we corroborated the association between IGF2BP3 and stemness traits within SACC cells. In vivo experiments further demonstrated that IGF2BP3 knockdown attenuated SACC tumor growth. In summary, this study provides a comprehensive understanding of IGF2BP3's function and regulatory mechanisms in SACC, offering vital theoretical support for future targeted therapeutic strategies involving IGF2BP3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.